Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study - PubMed
G Zanetti 1 ,
Article ImagesClinical Trial
. 2003 Nov;47(11):3442-7.
doi: 10.1128/AAC.47.11.3442-3447.2003.
F Bally, G Greub, J Garbino, T Kinge, D Lew, J-A Romand, J Bille, D Aymon, L Stratchounski, L Krawczyk, E Rubinstein, M-D Schaller, R Chiolero, M-P Glauser, A Cometta; Cefepime Study Group,
Affiliations
- PMID: 14576100
- PMCID: PMC253800
- DOI: 10.1128/AAC.47.11.3442-3447.2003
Clinical Trial
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al. Antimicrob Agents Chemother. 2003 Nov.
Abstract
In a randomized, evaluator-blind, multicenter trial, we compared cefepime (2 g three times a day) with imipenem-cilastatin (500 mg four times a day) for the treatment of nosocomial pneumonia in 281 intensive care unit patients from 13 centers in six European countries. Of 209 patients eligible for per-protocol analysis of efficacy, favorable clinical responses were achieved in 76 of 108 (70%) patients treated with cefepime and 75 of 101 (74%) patients treated with imipenem-cilastatin. The 95% confidence interval (CI) for the difference between these response rates (-16 to 8%) failed to exclude the predefined lower limit for noninferiority of -15%. In addition, therapy of pneumonia caused by an organism producing an extended-spectrum beta-lactamase (ESBL) failed in 4 of 13 patients in the cefepime group but in none of 10 patients in the imipenem group. However, the clinical efficacies of both treatments appeared to be similar in a secondary intent-to-treat analysis (95% CI for difference, -9 to 14%) and a multivariate analysis (95% CI for odds ratio, 0.47 to 1.75). Furthermore, the all-cause 30-day mortality rates were 28 of 108 (26%) patients in the cefepime group and 19 of 101 (19%) patients in the imipenem group (P = 0.25). Rates of documented or presumed microbiological eradication of the causative organism were similar with cefepime (61%) and imipenem-cilastatin (54%) (95% CI, -23 to 8%). Primary or secondary resistance of Pseudomonas aeruginosa was detected in 19% of the patients treated with cefepime and 44% of the patients treated with imipenem-cilastatin (P = 0.05). Adverse events were reported in 71 of 138 (51%) and 62 of 141 (44%) patients eligible for safety analysis in the cefepime and imipenem groups, respectively (P = 0.23). Although the primary end point for this study does not exclude the possibility that cefepime was inferior to imipenem, some secondary analyses showed that the two regimens had comparable clinical and microbiological efficacies. Cefepime appeared to be less active against organisms producing an ESBL, but primary and secondary resistance to imipenem was more common for P. aeruginosa. Selection of a single agent for therapy of nosocomial pneumonia should be guided by local resistance patterns.
Similar articles
-
Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group. Nakane T, et al. J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17. J Infect Chemother. 2015. PMID: 25239059 Clinical Trial.
-
Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, et al. Fink MP, et al. Antimicrob Agents Chemother. 1994 Mar;38(3):547-57. doi: 10.1128/AAC.38.3.547. Antimicrob Agents Chemother. 1994. PMID: 8203853 Free PMC article. Clinical Trial.
-
Torres A, Bauer TT, León-Gil C, Castillo F, Alvarez-Lerma F, Martínez-Pellús A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F. Torres A, et al. Thorax. 2000 Dec;55(12):1033-9. doi: 10.1136/thorax.55.12.1033. Thorax. 2000. PMID: 11083889 Free PMC article. Clinical Trial.
-
Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Zhanel GG, et al. Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Carbapenems in serious infections: a risk-benefit assessment.
Norrby SR. Norrby SR. Drug Saf. 2000 Mar;22(3):191-4. doi: 10.2165/00002018-200022030-00003. Drug Saf. 2000. PMID: 10738843 Review.
Cited by
-
Luque Paz D, Chean D, Tattevin P, Luque Paz D, Bayeh BA, Kouatchet A, Douillet D, Riou J. Luque Paz D, et al. Ann Intensive Care. 2024 Apr 25;14(1):66. doi: 10.1186/s13613-024-01291-5. Ann Intensive Care. 2024. PMID: 38662091 Free PMC article.
-
Hareza DA, Cosgrove SE, Simner PJ, Harris AD, Bergman Y, Conzemius R, Jacobs E, Beisken S, Tamma PD. Hareza DA, et al. Clin Infect Dis. 2024 May 15;78(5):1103-1110. doi: 10.1093/cid/ciad703. Clin Infect Dis. 2024. PMID: 37972276
-
Branton AC, Vu CH, Venugopalan V, Santevecchi BA, Cherabuddi K, Ramphal R, Manohar T, Desear KE. Branton AC, et al. JAC Antimicrob Resist. 2023 Mar 17;5(2):dlad021. doi: 10.1093/jacamr/dlad021. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36936190 Free PMC article.
-
Anderson DT, Albrecht B, Jones KA, Jacob JT, Sexton ME, Wiley Z, Dube WC, Lee B, Suchindran S. Anderson DT, et al. Open Forum Infect Dis. 2022 Feb 14;9(3):ofac034. doi: 10.1093/ofid/ofac034. eCollection 2022 Mar. Open Forum Infect Dis. 2022. PMID: 35174254 Free PMC article.
References
-
- Alvarez-Lerma, F., et al. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22:387-394. - PubMed
-
- Barckow, D., and C. D. Schwigon. 1993. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J. Antimicrob. Chemother. 32(Suppl. B):187-193. - PubMed
-
- Beam, T. R., D. N. Gilbert, C. M. Kunin, et al. 1992. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15(Suppl. 1):S5-S32. - PubMed
-
- Beam, T. R., D. N. Gilbert, and C. M. Kunin. 1993. European guidelines for anti-infective drug products. Introduction. Clin. Infect. Dis. 17:787-788. - PubMed
-
- Chastre, J., J. Y. Fagon, and J. Y. Fagon. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources